Upper Circuit: This micro-cap pharma stock reported stellar Q3FY23 results!
Upper Circuit: This micro-cap pharma stock reported stellar Q3FY23 results!

Upper Circuit: This micro-cap pharma stock reported stellar Q3FY23 results!

In an aim to expand their product portfolio, the company is focusing on developing multiple manufacturing sites

Bhavya Rathod Article rating: 3.7

They initiated contract manufacturing from three new locations this quarter and with this, they are currently manufacturing at nine locations across India

Only buyers: Shares of this pharmaceutical company are locked at 20 per cent upper circuit. Do you own it?
Only buyers: Shares of this pharmaceutical company are locked at 20 per cent upper circuit. Do you own it?

Only buyers: Shares of this pharmaceutical company are locked at 20 per cent upper circuit. Do you own it?

This stock is currently available at a PE multiple of 21.47 and an ROE of 9.68, all of which indicate good management effectiveness.

Kiran Shroff Article rating: 4.3

This stock is currently available at a PE multiple of 21.47 and an ROE of 9.68, all of which indicate good management effectiveness.

Shilpa Medicare skyrockets by 10.47 per cent on a weak market day!
Shilpa Medicare skyrockets by 10.47 per cent on a weak market day!

Shilpa Medicare skyrockets by 10.47 per cent on a weak market day!

The board of the company also has recommended a dividend of Rs 1.10 per equity share for the financial year ended March 31, 2022.  

Sayali Kotwal Article rating: 5.0

The shares of Shilpa Medicare soared 10.47 per cent to Rs 453.25 on BSE after the company announced promising results for the quarter that ended on March 31, 2022.

DSIJ MINDSHARE

Mkt Commentary30-May, 2023

Mindshare30-May, 2023

Multibaggers30-May, 2023

Bonus and Spilt Shares30-May, 2023

Multibaggers30-May, 2023

Knowledge

Fundamental28-May, 2023

Fundamental17-May, 2023

Fundamental13-May, 2023

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Investment in securities market are subject to market risks.Read all the related documents carefully before investing.
Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.